NCT00669825View on ClinicalTrials.gov

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Celiac Disease
Interventions
DRUG

ALV003

Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg

DRUG

Placebo

Placebo to be administered via intragastric tube

Trial Locations (2)

92103

Clinical Applications Laboratories, Inc., San Diego

Clinical Applications Laboratories, San Diego

Sponsors
All Listed Sponsors
lead

Alvine Pharmaceuticals Inc.

INDUSTRY

NCT00669825 - Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal | Biotech Hunter | Biotech Hunter